Cover Image
市場調查報告書

EpiCast Report:血友病的流行病學預測 (2024年)

EpiCast Report: Hemophilia - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 344637
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:血友病的流行病學預測 (2024年) EpiCast Report: Hemophilia - Epidemiology Forecast to 2026
出版日期: 2017年07月01日 內容資訊: 英文 39 Pages
簡介

所謂血友病是指X連鎖性·遺傳性的出血障礙,特徵是凝血因子中VII因子(A型血友病的情況) 或是IX因子 (B型血友病的情況)的生產、機能障礙的結果所造成凝血障礙。血友病患者(雖然也要看嚴重度)的關節、肌肉、軟組織、黏膜內部會自然發生出血,或是伴隨內傷或外傷的大量出血。全球9個國家確診的A、B型血友病患者數在2014年為60,671人(其中美國約佔28%),預測到2024年前將達到61,954人。由於血友病是遺傳性疾病,需要一輩子接受治療,但近年來由於高齡化及高血壓患者的增加,預測今後將需要血友病患者高血壓的對策。

本報告提供全球主要9個國家 (美國,德國,法國,義大利,西班牙,英國,日本,阿根廷,中國) 的A、B型血友病的發病情形與今後預測相關分析,提供您疾病的特徵,及目前患病者的發病情形,今後10年的患病數量的預測值等調查評估。

第1章 目錄

第2章 簡介

  • 疾病的概要
  • 相關分析
  • 出版預定的相關分析

第3章 流行病學的預測

  • 疾病的背景情況
  • 風險要素和共生病症
  • 全世界的趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • A型血友病的流行病學的預測 (今後11年份)
    • 確診的患病人數
    • 確診的患病人數:各年齡
    • 確診的患病人數:男女
    • 確診的患病人數 (年齡已調整)
  • B型血友病的流行病學的預測 (今後11年份)
    • 確診的患病人數
    • 確診的患病人數:各年齡
    • 確診的患病人數:男女
    • 確診的患病人數 (年齡已調整)
  • A、B型血友病的流行病學的預測 (今後11年份)
    • 確診的患病人數
    • 確診的患病人數:男女
  • 議論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER151-17

Hemophilia is an X-linked hereditary bleeding disorder, characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (FVIII) in hemophilia A or factor IX (FIX) in hemophilia B (Bolton-Maggs and Pasi, 2003). Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease (CDC, 2017b; Mayo Clinic, 2014).

In the 7MM, epidemiologists forecast an increase in the diagnosed prevalent cases of hemophilia A and hemophilia B, from 51,627 diagnosed prevalent cases in 2016 to 52,566 diagnosed prevalent cases in 2026, with an Annual Growth Rate (AGR) of 0.18% during the forecast period. The US will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B among the 7MM throughout the forecast period, while Spain will have the lowest.

Among the 7MM in 2016, the UK had the highest age-standardized diagnosed prevalence of hemophilia A in men with 20.36 cases per 100,000 population and in women with 0.60 cases per 100,000 population. The age-standardized diagnosed prevalence of hemophilia A in Germany was lowest in men with 9.61 cases per 100,000 population and in women with 0.28 cases per 100,000 population.

The report "EpiCast Report: Hemophilia - Epidemiology Forecast to 2026" provides an overview of the comorbidities and the global and historical trends for hemophilia in seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B by severity and with inhibitors were also provided in the report.

Scope

  • The Hemophilia EpiCast Report provides an overview of the risk factors and global trends of hemophilia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these seven markets.
  • The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Hemophilia EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
  • Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.
  • Identify the percentage of hemophilia prevalent cases by type.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Hemophilia: Executive Summary 5

  • 2.1 Related Reports 6
  • 2.2 Upcoming Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 8
  • 3.4 Forecast Methodology 10
    • 3.4.1 Sources 10
    • 3.4.2 Forecast Assumptions and Methods 13
    • 3.4.3 Diagnosed Prevalent Cases 14
    • 3.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity 15
    • 3.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitors 18
  • 3.5 Epidemiological Forecast for Hemophilia A (2016-2026) 19
    • 3.5.1 Diagnosed Prevalent Cases of Hemophilia A 19
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A 19
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A 20
    • 3.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity 21
    • 3.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors 22
  • 3.6 Epidemiological Forecast for Hemophilia B (2016-2026) 23
    • 3.6.1 Diagnosed Prevalent Cases of Hemophilia B 23
    • 3.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B 23
    • 3.6.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia B 24
    • 3.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity 25
    • 3.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors 27
  • 3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2016-2026) 27
    • 3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 27
    • 3.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 28
    • 3.7.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 29
    • 3.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity 30
    • 3.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors 31
  • 3.8 Discussion 32
    • 3.8.1 Epidemiological Forecast Insight 32
    • 3.8.2 Limitations of the Analysis 33
    • 3.8.3 Strengths of the Analysis 33

4 Appendix 35

  • 4.1 Bibliography 35
  • 4.2 About the Authors 37
    • 4.2.1 Epidemiologist 37
    • 4.2.2 Reviewers 37
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 38
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 38
  • 4.3 About GlobalData 39
  • 4.4 Contact Us 39
  • 4.5 Disclaimer 39

List of Tables

1.1 List of Tables

  • Table 1: Relationship of Bleeding Severity with Clotting Factor Level. 7
  • Table 2: Comorbidities for Hemophilia 8
  • Table 3: 7MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, Selected Years 2016-2026. 19
  • Table 4: 7MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026. 23
  • Table 5: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026. 28

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2016 and 2026 6
  • Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (Cases per 100,000 Population), All Ages, 2016 9
  • Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia B (Cases per 100,000 Population), All Ages, 2016 10
  • Figure 4: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 11
  • Figure 5: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity 12
  • Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors 13
  • Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016 20
  • Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016 21
  • Figure 9: 7MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2016 22
  • Figure 10: 7MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2016 22
  • Figure 11: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, 2016 24
  • Figure 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2016 25
  • Figure 13: 7MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2016 26
  • Figure 14: 7MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016 27
  • Figure 15: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2016 29
  • Figure 16: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2016 30
  • Figure 17: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2016 31
  • Figure 18: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016 32
Back to Top